血清S100A12及sRAGE对老年稳定性冠心病患者的影响
|
摘要
目的观察老年稳定性冠心病患者血清中钙粒蛋白S100A12和可溶性糖基化终产物受体(s RAGE)的表达及其相关影响因素。方法入选江苏省人民医院老年心血管科行冠脉造影检查诊断为稳定性冠心病的老年患者(年龄≥60岁)共74例,入院第二日晨空腹采集静脉血,测定生化各指标,于冠脉造影前采集桡动脉血,测定血清S100A12和s RAGE水平。同时入选冠脉造影示冠状动脉狭窄小于50%者共49例为对照组,同样测定上述各指标。结果老年稳定性冠心病患者血清S100A12水平较对照组明显上升,sRAGE水平明显下降,两者血清浓度呈显著的负相关(P<0.01)。老年稳定性冠心病患者是否合并高血压或糖尿病,对血清S100A12及sRAGE水平均无影响。但随着空腹血糖值的升高,S100A12水平升高,s RAGE水平下降,在血糖值≥10.0mmol/L,呈现出显著的组间差异(P<0.01)。结论 S100A12、s RAGE可作为老年稳定性冠心病的新型预测生物标志物,两者联合检验,可更好地评估病情。
Objective To obsereve the expression and related influencing factors of S100 A12 and s RAGE in the serum of the elderly with stable coronary heart disease(SCHD). Methods 123 cases(aged ≥60) underwent percutaneous coronary angiography(CAG) and were divided into 2 groups: SCHD group(n=74, with coronary stenosis≥50%) and control group(n=49, with coronary stenosis <50%); for all the 123 elderly cases, morning fasting venous blood samples were collected for biochemical test while blood samples drawn from radial arter were collected before CAG to detect the levels of S100 A12 and s RAGE in the serum. Results The serum level of S100 A12 was much higher while the level of s RAGE was much lower in the cases in SCHD group than in control group, and the serum concentrations of S100 A12 and s RAGE were in negative correlation(P<0.01); presence or absence of complicated hypertension or diabetes in cases in SCHD group were of no impact on the serum levels of S100 A12 and sRAGE while with the increase of fast blood glucose, the level of S100 A12 went up and the level of s RAGE dropped down, an obvious difference was found between the 2 groups when fasting blood glucose was ≥10.0 mmol/L(P<0.01). Conclusions S100 A12 and s RAGE may be taken as new predictive biomarkers for SCHD in the elderly and the joint detection can lead to a better disease evaluation.
Objective To obsereve the expression and related influencing factors of S100 A12 and s RAGE in the serum of the elderly with stable coronary heart disease(SCHD). Methods 123 cases(aged ≥60) underwent percutaneous coronary angiography(CAG) and were divided into 2 groups: SCHD group(n=74, with coronary stenosis≥50%) and control group(n=49, with coronary stenosis <50%); for all the 123 elderly cases, morning fasting venous blood samples were collected for biochemical test while blood samples drawn from radial arter were collected before CAG to detect the levels of S100 A12 and s RAGE in the serum. Results The serum level of S100 A12 was much higher while the level of s RAGE was much lower in the cases in SCHD group than in control group, and the serum concentrations of S100 A12 and s RAGE were in negative correlation(P<0.01); presence or absence of complicated hypertension or diabetes in cases in SCHD group were of no impact on the serum levels of S100 A12 and sRAGE while with the increase of fast blood glucose, the level of S100 A12 went up and the level of s RAGE dropped down, an obvious difference was found between the 2 groups when fasting blood glucose was ≥10.0 mmol/L(P<0.01). Conclusions S100 A12 and s RAGE may be taken as new predictive biomarkers for SCHD in the elderly and the joint detection can lead to a better disease evaluation.
引文
[1] M?ckel M, Searle J, Maisel A. The role of procalcitonin in acute heart failure patients[J]. ESC Heart Fail, 2017, 4(3):203-208.
[2] Yamamoto M, Sugimoto T. Advanced glycation end products,diabetes, and bone strength[J]. Curr Osteoporos Rep, 2016,14(6):320-326.
[3] Nazari A, Khorramdelazad H, Hassanshahi G, et al. S100A12in renal and cardiovascular diseases[J]. Life Sci, 2017, 191(191):253-258.
[4] Bangert A, Andrassy M, Muller AM, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease.[J] Proc Natl Acad Sci U S A, 2016, 113(2):E155-E164.
[5] Wirtz PH, von K? nel R. Psychological stress, inflammation,and coronary heart disease[J]. Curr Cardiol Rep, 2017, 19(11):111.
[6] Raggi P, Genest J, Giles JT, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions[J].Atherosclerosis, 2018, 276:98-108.
[7] Neviere R, Yu Y, Wang L, et al. Implication of advanced glycation end products(Ages)and their receptor(Rage)on myocardial contractile and mitochondrial functions[J]. Glycoconj J, 2016,33(4):607-617.
[8] Ziegler T, Horstkotte M, Lange P, et al. Endothelial RAGE exacerbates acute postischaemic cardiac inflammation[J]. Thromb Haemost, 2016, 116(2):300-308.
[9] Park KH, Park WJ. Endothelial dysfunction:clinical implications in cardiovascular disease and therapeutic approaches[J]. J Korean Med Sci, 2015, 30(9):1213-1225.
[10] Kitano D, Takayama T, Nagashima K, et al. A comparative study of time-specific oxidative stress after acute myocardial infarction in patients with and without diabetes mellitus[J]. BMC Cardiovasc Disord, 2016, 16:102.
[11] Jung ES, Chung W, Kim AJ, et al. Associations between Soluble Receptor for Advanced Glycation End Products(sRAGE)and S100A12(EN-RAGE)with Mortality in Long-term Hemodialysis Patients[J]. J Korean Med Sci, 2017, 32(1):54-59.
[12] Zhao P, Wu M, Yu H, et al. Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus[J]. J Investig Med, 2013, 61(5):861-866.
[13] Liu J, Ren YG, Zhang LH, et al. Serum S100A12 concentrations are correlated with angiographic coronary lesion complexity in patients with coronary artery disease[J]. Scand J Clin Lab Invest,2014, 74(2):149-154.
[14] Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death[J]. Diabetes,2013, 62(6):2116-2121.
[15] Falcone C, Bozzini S, Guasti L, et al. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease[J]. Scientific World Journal, 2013:584504.
[16] Falcone C, Bozzini S, D'angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis:possible correlation with clinical presentation[J].Dis Markers, 2013(35):135-140.
[2] Yamamoto M, Sugimoto T. Advanced glycation end products,diabetes, and bone strength[J]. Curr Osteoporos Rep, 2016,14(6):320-326.
[3] Nazari A, Khorramdelazad H, Hassanshahi G, et al. S100A12in renal and cardiovascular diseases[J]. Life Sci, 2017, 191(191):253-258.
[4] Bangert A, Andrassy M, Muller AM, et al. Critical role of RAGE and HMGB1 in inflammatory heart disease.[J] Proc Natl Acad Sci U S A, 2016, 113(2):E155-E164.
[5] Wirtz PH, von K? nel R. Psychological stress, inflammation,and coronary heart disease[J]. Curr Cardiol Rep, 2017, 19(11):111.
[6] Raggi P, Genest J, Giles JT, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions[J].Atherosclerosis, 2018, 276:98-108.
[7] Neviere R, Yu Y, Wang L, et al. Implication of advanced glycation end products(Ages)and their receptor(Rage)on myocardial contractile and mitochondrial functions[J]. Glycoconj J, 2016,33(4):607-617.
[8] Ziegler T, Horstkotte M, Lange P, et al. Endothelial RAGE exacerbates acute postischaemic cardiac inflammation[J]. Thromb Haemost, 2016, 116(2):300-308.
[9] Park KH, Park WJ. Endothelial dysfunction:clinical implications in cardiovascular disease and therapeutic approaches[J]. J Korean Med Sci, 2015, 30(9):1213-1225.
[10] Kitano D, Takayama T, Nagashima K, et al. A comparative study of time-specific oxidative stress after acute myocardial infarction in patients with and without diabetes mellitus[J]. BMC Cardiovasc Disord, 2016, 16:102.
[11] Jung ES, Chung W, Kim AJ, et al. Associations between Soluble Receptor for Advanced Glycation End Products(sRAGE)and S100A12(EN-RAGE)with Mortality in Long-term Hemodialysis Patients[J]. J Korean Med Sci, 2017, 32(1):54-59.
[12] Zhao P, Wu M, Yu H, et al. Serum S100A12 levels are correlated with the presence and severity of coronary artery disease in patients with type 2 diabetes mellitus[J]. J Investig Med, 2013, 61(5):861-866.
[13] Liu J, Ren YG, Zhang LH, et al. Serum S100A12 concentrations are correlated with angiographic coronary lesion complexity in patients with coronary artery disease[J]. Scand J Clin Lab Invest,2014, 74(2):149-154.
[14] Selvin E, Halushka MK, Rawlings AM, et al. sRAGE and risk of diabetes, cardiovascular disease, and death[J]. Diabetes,2013, 62(6):2116-2121.
[15] Falcone C, Bozzini S, Guasti L, et al. Soluble RAGE plasma levels in patients with coronary artery disease and peripheral artery disease[J]. Scientific World Journal, 2013:584504.
[16] Falcone C, Bozzini S, D'angelo A, et al. Plasma levels of soluble receptor for advanced glycation end products and coronary atherosclerosis:possible correlation with clinical presentation[J].Dis Markers, 2013(35):135-140.